WATERTOWN, Mass., July 22 /PRNewswire-USNewswire/ -- Biomodels LLC, a pre-clinical research organization best known for its expertise in oral mucositis, today announced it will further increase its work in the areas of cancer supportive care, pulmonary fibrosis, and biphosphonate-related osteoncrosis, with the promotion of Stephen T. Sonis DMD, DMSc to partner.
Dr. Sonis, a world-renowned expert in the clinical treatment and research of cancer regimen-related mucosal toxicities, said the company's collaborative work with pharmaceutical and biotechnology clients in the area of cancer supportive care is expected to grow sharply this year.
"The side effects of cancer treatment are becoming increasing important, as pharmaceutical and biotechnology companies realize that more effective dosing regimens can be achieved if side effects are considered and ameliorated at the pre-clinical stage," Dr. Sonis said.
Biomodels (www.biomodels.com) researchers have identified common mechanisms underlying toxicities that can lead to more rapid pharmaceutical interventions.
"Few people have the opportunity to help take a molecule from inception to patients, especially patients with great clinical need," Dr. Sonis said. "Biomodels' success in assisting industry to make the transition from test tube to the clinic as smoothly, quickly, safely and predictably as possible has been exciting for me.
"I look forward to our continued development of innovative models that expedite the clinical development process, especially to meet the challenges posed by regimen-related toxicities of cancer therapy," he added.
Biomodels is internationally known for its work in developing predictive animal models that are helping to determine which patients are predisposed to mucosit
|SOURCE Biomodels LLC|
Copyright©2009 PR Newswire.
All rights reserved